BR0305721A - Célula-tronco humana, população de células, processo para obtenção de células-tronco, para a produção de células diferenciadas da linhagem mesodérmica, para seleção que permite identificar agentes suscetìveis de apresentar uma atividade lipolìtica e uma atividade insulino-sensibilizante, utilização de uma célula, utilização de células-tronco, composição farmacêutica, célula humana, população celular humana multipotente - Google Patents

Célula-tronco humana, população de células, processo para obtenção de células-tronco, para a produção de células diferenciadas da linhagem mesodérmica, para seleção que permite identificar agentes suscetìveis de apresentar uma atividade lipolìtica e uma atividade insulino-sensibilizante, utilização de uma célula, utilização de células-tronco, composição farmacêutica, célula humana, população celular humana multipotente

Info

Publication number
BR0305721A
BR0305721A BR0305721-6A BR0305721A BR0305721A BR 0305721 A BR0305721 A BR 0305721A BR 0305721 A BR0305721 A BR 0305721A BR 0305721 A BR0305721 A BR 0305721A
Authority
BR
Brazil
Prior art keywords
cell
human
stem
cells
cell population
Prior art date
Application number
BR0305721-6A
Other languages
English (en)
Inventor
Christian Daniel
Gerard Ailhaud
Anne-Marie Rodriguez
Original Assignee
Saint Laurent Parfums
Centre Nat Rech Scient
Univ Nice Sophia Antipolis
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from FR0209799A external-priority patent/FR2843123B1/fr
Application filed by Saint Laurent Parfums, Centre Nat Rech Scient, Univ Nice Sophia Antipolis filed Critical Saint Laurent Parfums
Publication of BR0305721A publication Critical patent/BR0305721A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0662—Stem cells
    • C12N5/0667—Adipose-derived stem cells [ADSC]; Adipose stromal stem cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5014—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing toxicity
    • G01N33/5017—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing toxicity for testing neoplastic activity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G01N33/5023—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects on expression patterns
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5073—Stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/05—Inorganic components
    • C12N2500/10—Metals; Metal chelators
    • C12N2500/20—Transition metals
    • C12N2500/24—Iron; Fe chelators; Transferrin
    • C12N2500/25—Insulin-transferrin; Insulin-transferrin-selenium
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/30—Organic components
    • C12N2500/38—Vitamins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/30—Organic components
    • C12N2500/42—Organic phosphate, e.g. beta glycerophosphate
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/01—Modulators of cAMP or cGMP, e.g. non-hydrolysable analogs, phosphodiesterase inhibitors, cholera toxin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/11—Epidermal growth factor [EGF]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/115—Basic fibroblast growth factor (bFGF, FGF-2)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/125—Stem cell factor [SCF], c-kit ligand [KL]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/13—Nerve growth factor [NGF]; Brain-derived neurotrophic factor [BDNF]; Cilliary neurotrophic factor [CNTF]; Glial-derived neurotrophic factor [GDNF]; Neurotrophins [NT]; Neuregulins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/135—Platelet-derived growth factor [PDGF]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/30—Hormones
    • C12N2501/33—Insulin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/30—Hormones
    • C12N2501/38—Hormones with nuclear receptors
    • C12N2501/39—Steroid hormones
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/70—Enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00—Coculture with; Conditioned medium produced by
    • C12N2502/13—Coculture with; Conditioned medium produced by connective tissue cells; generic mesenchyme cells, e.g. so-called "embryonic fibroblasts"
    • C12N2502/1305—Adipocytes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2503/00—Use of cells in diagnostics
    • C12N2503/02—Drug screening
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/916—Hydrolases (3) acting on ester bonds (3.1), e.g. phosphatases (3.1.3), phospholipases C or phospholipases D (3.1.4)
    • G01N2333/918—Carboxylic ester hydrolases (3.1.1)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cell Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • Rheumatology (AREA)
  • General Engineering & Computer Science (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Materials For Medical Uses (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

"CéLULA-TRONCO HUMANA, POPULAçãO DE CéLULAS, PROCESSO PARA OBTENçãO DE CéLULAS-TRONCO, PARA A PRODUçãO DE CéLULAS DIFERENCIADAS DA LINHAGEM MESODéRMICA, PARA SELEçãO QUE PERMITE IDENTIFICAR AGENTES SUSCETìVEIS DE APRESENTAR UMA ATIVIDADE LIPOLìTICA E UMA ATIVIDADE INSULINO-SENSIBILIZANTE, UTILIZAçãO DE UMA CéLULA, UTILIZAçãO DE CéLULAS-TRONCO, COMPOSIçãO FARMACêUTICA, CéLULA HUMANA, POPULAçãO CELULAR HUMANA MULTIPOTENTE". A invenção refere-se a células-tronco humanas multipotentes e adultas, caracterizadas pelo fato de que elas apresentam: i) uma atividade de telomerase significativa, ii) um fenótipo HLA Classe I negativo, iii) um cariótipo normal, iv) uma capacidade de entrar em quiescência, V) uma capacidade de auto-renovação conservada durante pelo menos 130 duplicações de população.
BR0305721-6A 2002-07-31 2003-07-31 Célula-tronco humana, população de células, processo para obtenção de células-tronco, para a produção de células diferenciadas da linhagem mesodérmica, para seleção que permite identificar agentes suscetìveis de apresentar uma atividade lipolìtica e uma atividade insulino-sensibilizante, utilização de uma célula, utilização de células-tronco, composição farmacêutica, célula humana, população celular humana multipotente BR0305721A (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR0209799A FR2843123B1 (fr) 2002-07-31 2002-07-31 Cellules souches issues de tissu adipeux humain
FR0302657 2003-02-28
PCT/FR2003/002439 WO2004013275A2 (fr) 2002-07-31 2003-07-31 Cellules souches issues de tissu adipeux et cellules differenciees issues de ces cellules

Publications (1)

Publication Number Publication Date
BR0305721A true BR0305721A (pt) 2004-09-28

Family

ID=31497207

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0305721-6A BR0305721A (pt) 2002-07-31 2003-07-31 Célula-tronco humana, população de células, processo para obtenção de células-tronco, para a produção de células diferenciadas da linhagem mesodérmica, para seleção que permite identificar agentes suscetìveis de apresentar uma atividade lipolìtica e uma atividade insulino-sensibilizante, utilização de uma célula, utilização de células-tronco, composição farmacêutica, célula humana, população celular humana multipotente

Country Status (8)

Country Link
US (2) US8334135B2 (pt)
EP (1) EP1527161B1 (pt)
JP (1) JP4603883B2 (pt)
AU (1) AU2003278212B2 (pt)
BR (1) BR0305721A (pt)
CA (1) CA2493532C (pt)
ES (1) ES2560847T3 (pt)
WO (1) WO2004013275A2 (pt)

Families Citing this family (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2678490A1 (en) 2000-12-06 2002-06-13 Robert J. Hariri Isolated placental perfusate and placental cells isolated therefrom
US7311905B2 (en) 2002-02-13 2007-12-25 Anthrogenesis Corporation Embryonic-like stem cells derived from post-partum mammalian placenta, and uses and methods of treatment using said cells
KR101132545B1 (ko) * 2001-02-14 2012-04-02 안트로제네시스 코포레이션 산후 포유류의 태반, 이의 용도 및 태반 줄기세포
JP2004528021A (ja) * 2001-02-14 2004-09-16 アンスロジェネシス コーポレーション 分娩後の哺乳動物の胎盤、その使用およびそれに由来する胎盤幹細胞
US7771716B2 (en) 2001-12-07 2010-08-10 Cytori Therapeutics, Inc. Methods of using regenerative cells in the treatment of musculoskeletal disorders
US7585670B2 (en) 2001-12-07 2009-09-08 Cytori Therapeutics, Inc. Automated methods for isolating and using clinically safe adipose derived regenerative cells
US20050095228A1 (en) 2001-12-07 2005-05-05 Fraser John K. Methods of using regenerative cells in the treatment of peripheral vascular disease and related disorders
US8105580B2 (en) 2001-12-07 2012-01-31 Cytori Therapeutics, Inc. Methods of using adipose derived stem cells to promote wound healing
US9597395B2 (en) 2001-12-07 2017-03-21 Cytori Therapeutics, Inc. Methods of using adipose tissue-derived cells in the treatment of cardiovascular conditions
KR101083454B1 (ko) 2001-12-07 2011-11-16 사이토리 테라퓨틱스, 인크. 처리된 리포애스퍼레이트 세포로 환자를 치료하기 위한 시스템 및 방법
JP5019511B2 (ja) * 2003-09-17 2012-09-05 サイトリ セラピューティクス インコーポレイテッド 抹消血管疾患およびそれに関連する障害の治療において新生細胞を利用する方法
ES2313805B1 (es) * 2004-10-04 2009-12-23 Cellerix, S.L. Identificacion y aislamiento de celulas multipotentes de tejido mesenquimal no osteocondral.
US20060222634A1 (en) * 2005-03-31 2006-10-05 Clarke Diana L Amnion-derived cell compositions, methods of making and uses thereof
CN101218341A (zh) * 2005-05-05 2008-07-09 明尼苏达大学董事会 Nk细胞抑制作用用于促进定植的mhc-i阴性细胞持续存在的用途
WO2006128029A2 (en) * 2005-05-25 2006-11-30 University Of Virginia Patent Foundation Production of osteoclasts from adipose tissues
TW200726474A (en) * 2005-07-15 2007-07-16 Cognate Therapeutics Inc The immunophenotype and immunogenicity of human adipose derived cells
EP1909581A4 (en) * 2005-07-29 2008-12-31 Univ Virginia STEM CELLS OF ADIPOSE TISSUES, PERIVASCULAR CELLS AND PERICYTES
US7531355B2 (en) * 2005-07-29 2009-05-12 The Regents Of The University Of California Methods and compositions for smooth muscle reconstruction
PE20070771A1 (es) 2005-10-13 2007-08-11 Anthrogenesis Corp Inmunomodulacion mediante el uso de celulas madres de la placenta
CN101389754A (zh) 2005-12-29 2009-03-18 人类起源公司 胎盘干细胞和第二来源干细胞的联合培养
ES2708933T3 (es) 2005-12-29 2019-04-12 Celularity Inc Poblaciones de células madre placentarias
WO2008020329A2 (en) * 2006-05-11 2008-02-21 Regenics As Administration of cells and cellular extracts for rejuvenation
US7993918B2 (en) 2006-08-04 2011-08-09 Anthrogenesis Corporation Tumor suppression using placental stem cells
PT2084268T (pt) 2006-10-23 2019-01-28 Celularity Inc Métodos e composições para o tratamento de defeitos ósseos com populações de células placentárias
CA2670497A1 (en) * 2006-11-24 2008-05-29 Regents Of The University Of Minnesota Endodermal progenitor cells
RS52921B (en) 2007-02-12 2014-02-28 Anthrogenesis Corporation TREATMENT OF INFLAMMATORY DISEASES USING PLACENTAL CELL CELLS
WO2008109063A2 (en) * 2007-03-01 2008-09-12 Cryo-Cell International, Inc. Procurement, isolation and cryopreservation of endometrial/menstrual cells
ES2530995T3 (es) 2007-09-28 2015-03-09 Anthrogenesis Corp Supresión de tumor usando perfusato placentario humano y células asesinas naturales intermediarias que provienen de placenta humana
GB0803076D0 (en) 2008-02-20 2008-03-26 Univ Ghent Mucosal Membrane Receptor and uses thereof
WO2010021993A1 (en) 2008-08-19 2010-02-25 Cytori Therapeutics, Inc. Methods of using adipose tissue-derived cells in the treatment of the lymphatic system and malignant disease
EP2329012B1 (en) 2008-08-20 2020-05-20 Celularity, Inc. Treatment of stroke using isolated placental cells
NZ591292A (en) 2008-08-20 2012-10-26 Anthrogenesis Corp Improved cell composition and methods of making the same
CA2734446C (en) 2008-08-22 2017-06-20 Anthrogenesis Corporation Methods and compositions for treatment of bone defects with placental cell populations
JP5869342B2 (ja) 2008-11-19 2016-02-24 アンスロジェネシス コーポレーション 羊膜由来接着細胞
US9192695B2 (en) 2008-11-20 2015-11-24 Allosource Allografts combined with tissue derived stem cells for bone healing
JP5917392B2 (ja) 2009-05-01 2016-05-11 ビミニ テクノロジーズ リミテッド ライアビリティ カンパニー 組織及び細胞富化グラフトを最適化するシステム、方法及び組成物
WO2011032025A2 (en) * 2009-09-10 2011-03-17 The Salk Institute For Biological Studies Adipose-derived induced pluripotent stem cells
EP3284818B1 (en) 2010-01-26 2022-03-09 Celularity Inc. Treatment of bone-related cancers using placental stem cells
TW202011974A (zh) 2010-04-07 2020-04-01 美商安瑟吉納西斯公司 利用胎盤幹細胞之血管新生
TW201138792A (en) 2010-04-08 2011-11-16 Anthrogenesis Corp Treatment of sarcoidosis using placental stem cells
US9352003B1 (en) 2010-05-14 2016-05-31 Musculoskeletal Transplant Foundation Tissue-derived tissuegenic implants, and methods of fabricating and using same
US8883210B1 (en) 2010-05-14 2014-11-11 Musculoskeletal Transplant Foundation Tissue-derived tissuegenic implants, and methods of fabricating and using same
US10130736B1 (en) 2010-05-14 2018-11-20 Musculoskeletal Transplant Foundation Tissue-derived tissuegenic implants, and methods of fabricating and using same
WO2012009422A1 (en) 2010-07-13 2012-01-19 Anthrogenesis Corporation Methods of generating natural killer cells
US8895291B2 (en) 2010-10-08 2014-11-25 Terumo Bct, Inc. Methods and systems of growing and harvesting cells in a hollow fiber bioreactor system with control conditions
JP5778412B2 (ja) * 2010-11-29 2015-09-16 花王株式会社 Ｃｇｒｐ応答調節剤の評価又は選択方法
AR093183A1 (es) 2010-12-31 2015-05-27 Anthrogenesis Corp Aumento de la potencia de celulas madre de placenta usando moleculas de arn moduladoras
US8834928B1 (en) 2011-05-16 2014-09-16 Musculoskeletal Transplant Foundation Tissue-derived tissugenic implants, and methods of fabricating and using same
TWI602570B (zh) 2011-06-01 2017-10-21 安瑟吉納西斯公司 使用胎盤幹細胞之疼痛治療
WO2013055476A1 (en) 2011-09-09 2013-04-18 Anthrogenesis Corporation Treatment of amyotrophic lateral sclerosis using placental stem cells
CA2882561A1 (en) * 2012-08-20 2014-02-27 Boston Medical Center Corporation Assays, systems, and methods for obtaining personalized anabolic profiles
JP5856029B2 (ja) * 2012-08-31 2016-02-09 阿部　博幸 間葉系幹細胞を未分化増殖させる方法、および間葉系幹細胞を濃縮する方法
WO2014057097A1 (en) 2012-10-12 2014-04-17 INSERM (Institut National de la Santé et de la Recherche Médicale) Modulated mesenchymal stem cells for cardiac cell therapy
WO2014123879A1 (en) 2013-02-05 2014-08-14 Anthrogenesis Corporation Natural killer cells from placenta
WO2014150784A1 (en) 2013-03-15 2014-09-25 Allosource Cell repopulated collagen matrix for soft tissue repair and regeneration
WO2015017500A1 (en) 2013-07-30 2015-02-05 Musculoskeletal Transplant Foundation Acellular soft tissue-derived matrices and methods for preparing same
CN105992816B (zh) 2013-11-16 2018-04-17 泰尔茂比司特公司 生物反应器中的细胞扩增
EP3613841B1 (en) 2014-03-25 2022-04-20 Terumo BCT, Inc. Passive replacement of media
JP6830059B2 (ja) 2014-09-26 2021-02-17 テルモ ビーシーティー、インコーポレーテッド スケジュール化された細胞フィーディング
CA3177726A1 (en) 2015-05-21 2016-11-24 Musculoskeletal Transplant Foundation Modified demineralized cortical bone fibers
WO2017004592A1 (en) 2015-07-02 2017-01-05 Terumo Bct, Inc. Cell growth with mechanical stimuli
US10912864B2 (en) 2015-07-24 2021-02-09 Musculoskeletal Transplant Foundation Acellular soft tissue-derived matrices and methods for preparing same
US11052175B2 (en) 2015-08-19 2021-07-06 Musculoskeletal Transplant Foundation Cartilage-derived implants and methods of making and using same
WO2017205667A1 (en) 2016-05-25 2017-11-30 Terumo Bct, Inc. Cell expansion
US11685883B2 (en) 2016-06-07 2023-06-27 Terumo Bct, Inc. Methods and systems for coating a cell growth surface
US11104874B2 (en) 2016-06-07 2021-08-31 Terumo Bct, Inc. Coating a bioreactor
US11624046B2 (en) 2017-03-31 2023-04-11 Terumo Bct, Inc. Cell expansion
CN117247899A (zh) 2017-03-31 2023-12-19 泰尔茂比司特公司 细胞扩增
WO2018237125A1 (en) * 2017-06-21 2018-12-27 University Of North Carolina At Greensboro AUTOLOGOUS HUMAN MASTOCYTES FROM ADIPOSE TISSUE, COMPOSITIONS AND RELATED METHODS

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS591415A (ja) * 1982-06-28 1984-01-06 Mochida Pharmaceut Co Ltd 循環系疾患治療剤
US5733542A (en) * 1990-11-16 1998-03-31 Haynesworth; Stephen E. Enhancing bone marrow engraftment using MSCS
US5589483A (en) * 1994-12-21 1996-12-31 Geron Corporation Isoquinoline poly (ADP-ribose) polymerase inhibitors to treat skin diseases associated with cellular senescence
US6875741B2 (en) * 1998-09-02 2005-04-05 Renuka Pillutla Insulin and IGF-1 receptor agonists and antagonists
US20030082152A1 (en) * 1999-03-10 2003-05-01 Hedrick Marc H. Adipose-derived stem cells and lattices
KR100968164B1 (ko) 1999-03-10 2010-07-06 더 리전츠 오브 더 유니버시티 오브 캘리포니아 지방 유래 간세포 및 격자
CA2852534A1 (en) 1999-08-05 2001-02-15 Abt Holding Company Multipotent adult stem cells and methods for isolation
EP1218489B1 (en) * 1999-09-24 2009-03-18 Cybios LLC Pluripotent embryonic-like stem cells, compositions, methods and uses thereof
JP2004529621A (ja) * 2001-02-14 2004-09-30 ティー ファークト，レオ 多能性成体幹細胞、その起源、それを得る方法および維持する方法、それを分化させる方法、その使用法、ならびにそれ由来の細胞

Also Published As

Publication number Publication date
US20130084270A1 (en) 2013-04-04
JP4603883B2 (ja) 2010-12-22
WO2004013275A2 (fr) 2004-02-12
EP1527161B1 (fr) 2015-10-28
US20040229351A1 (en) 2004-11-18
CA2493532A1 (fr) 2004-02-12
JP2005534314A (ja) 2005-11-17
ES2560847T3 (es) 2016-02-23
EP1527161A2 (fr) 2005-05-04
AU2003278212B2 (en) 2009-07-09
AU2003278212A1 (en) 2004-02-23
CA2493532C (fr) 2014-05-27
WO2004013275A8 (fr) 2004-10-21
WO2004013275A3 (fr) 2004-04-29
US8334135B2 (en) 2012-12-18

Similar Documents

Publication Publication Date Title
BR0305721A (pt) Célula-tronco humana, população de células, processo para obtenção de células-tronco, para a produção de células diferenciadas da linhagem mesodérmica, para seleção que permite identificar agentes suscetìveis de apresentar uma atividade lipolìtica e uma atividade insulino-sensibilizante, utilização de uma célula, utilização de células-tronco, composição farmacêutica, célula humana, população celular humana multipotente
BR0315435A (pt) Distribuição de vegf com base na célula
ATE439429T1 (de) Multipotente neurale stammzellen aus hautgewebe und deren verwendungen
ATE337015T1 (de) Aus ganzen zellen bestehender impfstoff, der staphylococcus aureus antigen enthält
BRPI9912227A (pt) método para diagnóstico precoce in vitro de carcinomas e de seus estágios iniciais e kit para realização do método.
JP2001520878A5 (pt)
WO2002041906A3 (en) Methods and apparatus for producing gender enriched sperm
BRPI0612423A2 (pt) estabelecimento de linhagem de cÉlulas-tronco embrionÁrias humanas usando cÉlulas de mamÍferos
BR9806296A (pt) Derivados de ácido sulfìnico e sua preparação e uso
ES2056854T3 (es) Tiadiazinonas.
SG165418A1 (en) Cell populations having immunoregulatory activity, method for isolation and uses
ME00731B (me) Primena dialkil fumarata
EP1491093A3 (en) Multipotent adult stem cells, sources thereof, methods of obtaining and maintaining same, methods of differentiation thereof, methods of use thereof and cells derived thereof
Kvist et al. Sperm nuclear zinc, chromatin stability, and male fertility
BR9811113A (pt) Composição para o cuidado da pele, e, processos cosméticos para liberar um fitoestrogênio para a pele humana, processo para melhorar a aparência da pele, para melhorar a proliferação de fibroblastos na pele humana, e para melhorar a proliferação de células da pele epidérmica
ATE87213T1 (de) Potenzierung der erythropoiesis.
EE03955B1 (et) Nukleiinhappe kasutamine ravimi valmistamiseks imetaja reproduktiivtrakti vähemalt mõne raku transfekteerimiseks
DE60002185T2 (de) Transplantation von hämatopoietischen zellen
BR0013844A (pt) Restauração de telÈmero e extensão de perìodo de vida da célula em animais clonados de células somáticas senescentes
ES2172770T3 (es) Composiciones de pastillas de jabon coladas en molde que contienen bajos contenidos de agua y minimas proporciones entre poliol y agua.
ATE521696T1 (de) Verfahren zur herstellung von zelltransplantaten
DK0793503T3 (da) Anvendelse af hepatocyt-vækstfaktor til inducering af profilerering og differentiering af hemotopoietiske celler
ATE202283T1 (de) Spermaverdünner der natives phosphocaseinat oder beta lactoglobulin enthält, verfahren zu seiner herstellung und seine verwendungen
BR0110072A (pt) Células pluripotentes compreendendo núcleo alogênico e mitocÈndria
FR2801979B1 (fr) Utilisation d'un anticorps specifique des fibroblastes papillaires comme marqueur de qualite d'une peau

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B15K Others concerning applications: alteration of classification

Ipc: C12N 5/0775 (2010.01), G01N 33/50 (2006.01), A61K

B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 15A ANUIDADE.

B08G Application fees: restoration [chapter 8.7 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL